Endurant Capital Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AXNX
Axonics, Inc. Common Stock
AXNX
|
+$1.39M |
| 2 |
Icon
ICLR
|
+$947K |
| 3 |
Labcorp
LH
|
+$837K |
| 4 |
Encompass Health
EHC
|
+$834K |
| 5 |
Pfizer
PFE
|
+$477K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioMarin Pharmaceuticals
BMRN
|
+$15.5M |
| 2 |
Bruker
BRKR
|
+$6.93M |
| 3 |
AstraZeneca
AZN
|
+$6.53M |
| 4 |
Elevance Health
ELV
|
+$5.03M |
| 5 |
Thermo Fisher Scientific
TMO
|
+$4.87M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.36% |
| 2 | Real Estate | 1.64% |
No holdings matched the selected filter criteria.
Similar funds
Endurant Capital Management's Q4 2023 Portfolio in Review
As of Q4 2023, Endurant Capital Management held 52 positions worth $17.4M, down 84% from $111M the previous quarter. Its ten largest holdings account for 70% of the portfolio.
Endurant Capital Management withdrew a net $95.1M in Q4 2023, closing 27 positions and reducing 16 holdings. Its most notable exit was Bruker, an estimated $6.93M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 95% a quarter earlier, followed by Real Estate.
Against the trend, Endurant Capital Management opened a new position in Axonics, Inc. Common Stock worth $1.55M.
- Endurant Capital Management's largest Q4 2023 buy was Axonics, Inc. Common Stock: 24,871 shares worth $1.55M.
- Endurant Capital Management's biggest Q4 2023 reduction was BioMarin Pharmaceuticals, cutting an estimated $15.5M.
- Endurant Capital Management fully exited Bruker in Q4 2023, selling an estimated $6.93M.
- Endurant Capital Management's ten largest holdings make up 70% of its $17.4M portfolio in Q4 2023.
- Endurant Capital Management opened 9 new positions and closed 27 in Q4 2023.
- Endurant Capital Management's portfolio value fell 84% quarter-over-quarter to $17.4M.
Based on Endurant Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.